About the Approval Cipla Limited, a leading pharmaceutical company, has secured final approval from the USFDA for its generic version of Somatuline Depot (lanreotide) Injection. This approval opens doors for Cipla to enter the lucrative US market for the treatment of Acromegaly and Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs), estimated at approximately USD 898 million annually. Cipla’s …